Inclusion Criteria:  Patient is at least 18 years of age at the day of screening. Confirmed HCV infection by PCR and known genotype (GT) 1, 4, 5, or 6. Female lactating patient, who will wean their children on starting treatment and ensure not to breastfeed after start treatment. Patients with an indication for SOF/DAC treatment for the treatment of chronic HCV. Patient is able and willing to sign the Informed Consent Form. Patient is able and willing to follow protocol requirements.  Exclusion Criteria:  Need for co-treatment with ribavirin. HepBSAg positive test at screening. Treatment with rosuvastatin. Medicinal products that are potent P-glycoprotein (P-gp) and or CYP3A4 inducers in the intestine (rifampicin, rifabutin, St. John's wort [Hypericum perforatum], carbamazepine, phenobarbital and phenytoin). HIV co-infected patients using antiretroviral agents possibly interacting with SOF/DAC. Drugs associated with bradycardia including amiodarone. History of heart block. eGFR < 30 ml/min/1.73 m2. Compensated cirrhosis, based on historical data, evidence of decompensated cirrhosis by ascites, encephalopathy, or variceal hemorrhage and/or abnormal ALT/AST/INR/thrombocytes indicating cirrhosis. Relevant history or current condition that might interfere with drug absorption, distribution, metabolism or excretion except for conditions related to HCV. Clinically relevant low hemoglobin concentration at screening. Pregnancy Refusal to use proper contraception during treatment